PDF(Pubmed)
Abstract：
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new treatments have been developed and approved for these patients, among them of particular relevance are those targeting CD19. Tafasitamab is a humanized monoclonal antibody targeting CD19, composed of a modified fragment crystallizable (Fc) region engineered with higher affinity for Fc gamma receptors (FcγR) receptors, leading to increased cytotoxicity through natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis). In this product review, we will discuss its mechanism of action, safety profile and efficacy results from clinical trials that led to its approval in combination with lenalidomide for patients with R/R DLBCL ineligible for high-dose chemotherapy and autologous transplantation.
摘要：
复发或难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL）患者需要额外的治疗，特别是那些不合格或不响应大剂量细胞毒性化疗和干细胞移植。在过去的几年里，已经为这些患者开发并批准了几种新的治疗方法，其中特别相关的是靶向CD19的那些.Tafasitamab是一种针对CD19的人源化单克隆抗体，由修饰的片段可结晶（Fc）区组成，对Fcγ受体（FcγR）受体具有更高的亲和力，导致通过自然杀伤细胞和巨噬细胞增加的细胞毒性（抗体依赖性细胞毒性和抗体依赖性细胞介导的吞噬作用）。在本产品评论中，我们将讨论它的作用机制，来自临床试验的安全性和有效性结果，这些临床试验导致其与来那度胺联合用于不适合大剂量化疗和自体移植的R/RDLBCL患者。
